Alzheimer’s disease has no single cause. It results from a combination of biological processes, genetic predisposition, vascular health, and lifestyle factors that interact over decades. The disease accounts for 60 to 70% of all dementia cases worldwide, affecting an estimated 34 million people globally. Understanding what drives it means looking at several overlapping mechanisms, each of which damages the brain in a different way.
Two Toxic Proteins That Destroy Brain Cells
The hallmark damage in Alzheimer’s involves two proteins that malfunction and accumulate in the brain: amyloid-beta and tau. Both are normal proteins that exist in healthy brains, but in Alzheimer’s they become corrupted versions of themselves.
Amyloid-beta is produced when a larger protein on the surface of neurons gets cut apart by enzymes. Normally, the protein is snipped in a way that’s harmless. But in Alzheimer’s, enzymes cut it at the wrong locations, producing sticky fragments that clump together outside neurons. These clumps, called plaques, are toxic to surrounding brain tissue. The most dangerous fragment is a 42-amino-acid version that is especially prone to aggregating into dense deposits. In a healthy brain, a different enzyme cuts the protein in a way that prevents this fragment from forming at all.
Tau protein is the second culprit, and it attacks from inside the neuron. Tau normally acts like railroad ties for the cell’s internal transport system, stabilizing the structural tubes that carry nutrients and signals from one end of the neuron to the other. In Alzheimer’s, tau becomes overloaded with chemical tags (phosphate groups) that cause it to detach from those tubes and collapse them. Worse, the damaged tau pulls healthy tau proteins away from the structures they’re supporting, spreading the destruction. The dislodged tau then clumps into tangled fibers inside the cell. With their internal transport system destroyed, neurons can no longer communicate or sustain themselves, and they slowly die.
These two processes feed each other. Amyloid plaques on the outside of cells trigger inflammatory signals that accelerate tau damage on the inside. The combination leads to progressive shrinkage of brain tissue, starting in areas responsible for memory.
The Brain’s Immune System Turns Against Itself
The brain has its own immune cells, and in Alzheimer’s they shift from being protective to destructive. Early in the disease, these cells cluster around amyloid plaques and attempt to clear them. This is a helpful response. But as the disease progresses and plaques keep accumulating, the immune cells become chronically activated and switch into an inflammatory state.
Once in this state, they release molecules that damage nearby neurons. Those injured neurons then release more toxic amyloid, which pushes the immune cells further into their inflammatory mode. This creates a vicious cycle: damaged neurons provoke more inflammation, which damages more neurons. Over time, this unchecked inflammation drives widespread neuron death and brain tissue shrinkage. Researchers have identified two distinct peaks of immune cell activity in Alzheimer’s: an early protective phase during the preclinical stage, and a later harmful, inflammatory phase once symptoms appear.
Genetic Risk: APOE4 and Rare Mutations
The strongest genetic risk factor for common, late-onset Alzheimer’s is a variant of a gene called APOE. Everyone carries two copies of this gene, and the version called APOE4 significantly raises risk. People who inherit two copies of APOE4 have roughly a 60% chance of developing Alzheimer’s dementia by age 85. In postmortem studies, nearly all people with two APOE4 copies showed Alzheimer’s brain pathology from age 55 onward, compared to about half of those without the variant. APOE4 is also linked to a thinner protective barrier around brain blood vessels and greater leakage of blood proteins into brain tissue, which accelerates damage through separate pathways.
A rarer form of Alzheimer’s strikes earlier, sometimes in a person’s 40s or 50s. This early-onset type is caused by inherited mutations in three specific genes: APP, PSEN1, and PSEN2. These mutations are dominant, meaning a single copy from one parent is enough to cause disease. They work by altering the enzymes that cut amyloid precursor protein, shifting production toward the more toxic, clump-prone form of amyloid-beta. Some PSEN1 mutations arise spontaneously rather than being inherited, which means a person can develop familial Alzheimer’s even without a known family history.
Blood Vessel Damage as an Early Trigger
Alzheimer’s is not purely a disease of proteins and genes. Vascular damage, particularly to the tiny blood vessels that feed the brain, plays a role that researchers increasingly consider central rather than secondary. The blood-brain barrier is a tightly sealed lining of blood vessels that normally prevents toxins in the bloodstream from reaching brain tissue. In Alzheimer’s, this barrier breaks down early, often before any symptoms of dementia appear.
More than 20 independent postmortem studies have confirmed this breakdown, finding leaked blood proteins, immune molecules, and even red blood cells in the brain tissue of Alzheimer’s patients. When these substances enter the brain, they trigger inflammation, activate immune cells, and directly injure neurons. One prominent theory proposes a “two-hit” model: vascular damage is the first hit, sufficient on its own to start killing neurons, and the resulting impaired blood flow then promotes amyloid buildup as the second hit. For people carrying the APOE4 gene variant, this barrier breakdown is more severe, connecting genetic risk directly to vascular vulnerability.
Insulin Resistance in the Brain
The brain depends heavily on glucose for energy, and insulin plays a key role in helping neurons absorb and use it. In Alzheimer’s, brain cells become resistant to insulin, meaning they can no longer efficiently take up glucose even when it’s available. This energy crisis impairs the brain’s ability to form memories, maintain connections between neurons, and clear toxic waste products like amyloid.
The link between Alzheimer’s and insulin resistance is strong enough that some researchers have described Alzheimer’s as “type 3 diabetes.” Impaired insulin signaling in the brain doesn’t just starve neurons of fuel. It also directly promotes amyloid plaque formation and interferes with the mechanisms that would normally clear amyloid from the brain. People with type 2 diabetes face a substantially higher risk of Alzheimer’s, and the metabolic dysfunction seen in both conditions shares overlapping pathways: chronic inflammation, impaired energy metabolism, and neurotoxin accumulation.
Sleep and the Brain’s Waste Clearance System
The brain has a dedicated waste-removal network that flushes toxins out through channels surrounding blood vessels. This system is largely inactive during waking hours. When you fall into deep sleep, the spaces between brain cells expand, fluid flow increases, and metabolic waste, including amyloid-beta, gets swept away. The vast majority of this clearance happens during sleep.
Alzheimer’s patients consistently show shorter total sleep time, more frequent awakenings, and significantly impaired deep sleep compared to healthy adults. Poor sleep reduces the brain’s ability to clear amyloid, leading to greater accumulation. Greater amyloid accumulation, in turn, further disrupts sleep. This bidirectional relationship means that chronic sleep problems over years or decades can meaningfully contribute to Alzheimer’s pathology. Factors that improve this waste clearance system include regular exercise, adequate sleep duration, and moderate alcohol intake.
Air Pollution and Environmental Exposures
Fine particulate matter in air pollution, particles small enough to penetrate deep into the lungs, can reach the brain through two routes. The first is direct: inhaled particles travel from the nasal passages along the olfactory nerve into the brain’s smell-processing center. The second is indirect: particles enter the bloodstream through the lungs and cross the compromised blood-brain barrier. Once in the brain, these particles trigger the same inflammatory cascades seen in Alzheimer’s, activating immune cells and promoting both amyloid and tau pathology.
Animal studies have shown that sustained exposure to fine particulate matter causes neuron death and disorganization in the brain’s olfactory region, along with significantly elevated levels of abnormal tau protein. In humans, long-term exposure to polluted air has been linked to higher rates of cognitive decline and dementia. This environmental pathway may help explain why Alzheimer’s rates vary geographically and why the disease is projected to grow as urbanization increases worldwide.